There were 2,055 press releases posted in the last 24 hours and 428,765 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Sunesis Pharmaceuticals Announces First Subject Dosed in Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image